For example, the Spain BIA in T2DM that uses basal-bolus insulin showed a potential cost-saving in this patient group [15], a finding that was echoed in the USA BIA of T2DM patients on intensive insulin treatment [16] and the Argentina BIA of T2DM patients on multiple daily insulin [17]. This evidence concerns the gene INS and type 2 diabetes mellitus.